Table 3.
Characteristics of patients, who died during treatment, discontinued treatment prematurely, or suffered from virological relapse after end of treatment
| Age (yr) | Sex | BL viral load, IU/mL | GT | LCi | BL MELD | Previous treatment | Current treatment | Treatment duration | Cause for premature discontinuation | Outcome | RAV NS3 protease | RAV NS5A | RAV NS5B polymerase | |
| Patients, who died during treatment, or discontinued treatment prematurely | ||||||||||||||
| No. 1 | 63 | male | 1.41 Mio | 1b | Yes | 12 | PR | SOF/SMV | 12 | Sepsis | death | |||
| No. 2 | 66 | male | 1.69 Mio | 1b | Yes, HTx | 14 | - | SOF/LDV | 5 | Intracranial bleeding | death | |||
| No. 3 | 55 | male | 56200 | 1b | Yes, LTx | 24 | TVR/PR | SOF/SMV/R | 14 | Re-LTx, sepsis | death | |||
| No. 4 | 49 | male | 157000 | 1a | Yes, | 14 | PR | SOF/LDV/R | 8 | Right-heart failure | death | |||
| No. 5 | 79 | female | 5.85 Mio | 1b | Yes | 6 | TVR/PR | SOF/SMV | 10 | Back-pain | SVR 24 | |||
| No. 6 | 55 | male | 396000 | 1a | Yes, TIPSS | 10 | PR | SOF/DCV | 16 | Hepatic encephalopathy | SVR 24 | |||
| Patients with relapse after end of treatment | ||||||||||||||
| No. 7 | 54 | male | 10300 | 1a | Yes | 8 | PR | SOF/PR | 12 | NA | NA | NA | ||
| No. 8 | 63 | male | 321000 | 1b | - | 6 | - | SOF/PR | 12 | NA | NA | NA | ||
| No. 9 | 43 | female | 408000 | 1a | Yes | 8 | - | SOF/PR | 12 | NA | NA | NA | ||
| No. 10 | 40 | male | 2.74 Mio | 1b | - | 6 | PR | SOF/PR | 12 | NA | NA | NA | ||
| No. 11 | 48 | male | 4.89 Mio | 3a | No, LTx | 11 | PR | SOF/DCV/R | 24 | F43F/L | A30K | - | ||
| No. 12 | 56 | female | 1.38 Mio | 3a | Yes | 7 | PR | SOF/DCV | 24 | - | Y93H | S282S/T | ||
| No. 13 | 38 | male | 3.39 Mio | 1b | - | 6 | - | SOF/DCV | 12 | Q80K | L31M, Y93H | - | ||
| No. 14 | 52 | male | 2.47 Mio | 3a | Yes | 10 | - | SOF/DCV/R | 24 | - | Y93H | - | ||
| No. 15 | 55 | female | 3.03 Mio | 1a | - | 6 | TVR/PR | SOF/DCV | 12 | T54S, R155K | L31M/L | - | ||
| No. 16 | 49 | male | 8340 | 3 | Yes | 6 | - | SOF/LDV/R | 24 | - | A30S | - | ||
| No. 17 | 52 | male | 239000 | 1b | Yes | 6 | - | SOF/LDV/R | 12 | T54S, V55I, Q80K | Q30E | - | ||
| No. 18 | 57 | male | 137 (on SOF/R) | 1a | Yes, HCC | 11 | SOF/R | SOF/DCV | 12 | - | L31M, P58S, Y93C | - | ||
BL: Baseline; GT: Genotype; HCC: Hepatocellular carcinoma; LCi: Liver cirrhosis; MELD: Model of end stage liver disease; P: Pegylated Interferon; R: Ribavirin; SOF: Sofosbuvir; SMV: Simeprevir; LDV: Ledipasvir; DCV: Daclatasvir; TVR: Telaprevir; RAV: Resistance associated variant; HTx: Heart transplantation; LTx: Liver transplantation; TIPSS: Transjugular portosystemic stent shunt; NA: Not available.